Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC
Brief Summary:
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.